Quantum Biopharma, Indivior, Canopy Growth, Aurora Cannabis, Incannex Healthcare, Tilray, and Gibraltar Industries are the seven Cannabis stocks to watch today, according to MarketBeat's stock screener tool. Cannabis stocks are shares of publicly traded companies involved in the legal marijuana industry—ranging from cultivation and processing to distribution, retail operations and ancillary services such as packaging or testing. Their performance is heavily influenced by shifting regulatory landscapes, consumer demand and broader market sentiment around legalization. As a result, these securities tend to exhibit higher volatility and speculative risk compared with more established sectors. These companies had the highest dollar trading volume of any Cannabis stocks within the last several days.
Quantum Biopharma (QNTM)
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.
NASDAQ:QNTM traded up $5.00 during trading hours on Tuesday, reaching $26.45. The company had a trading volume of 555,193 shares, compared to its average volume of 947,842. Quantum Biopharma has a 52 week low of $2.70 and a 52 week high of $29.69. The firm has a market cap of $71.56 million, a price-to-earnings ratio of -1.70 and a beta of 0.55. The firm's 50 day moving average price is $10.35 and its 200-day moving average price is $7.12.
Read Our Latest Research Report on QNTM
Indivior (INDV)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Shares of Indivior stock traded down $0.26 on Tuesday, hitting $13.92. 415,229 shares of the company's stock were exchanged, compared to its average volume of 1,096,283. The company has a 50-day simple moving average of $11.41 and a 200-day simple moving average of $10.98. The stock has a market capitalization of $1.92 billion, a PE ratio of -39.77 and a beta of 0.66. Indivior has a 1 year low of $7.33 and a 1 year high of $16.98.
Read Our Latest Research Report on INDV
Canopy Growth (CGC)
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments.
Shares of CGC traded down $0.07 during trading hours on Tuesday, reaching $1.39. 4,096,249 shares of the stock traded hands, compared to its average volume of 6,050,298. The company has a current ratio of 3.52, a quick ratio of 2.58 and a debt-to-equity ratio of 0.74. Canopy Growth has a 52-week low of $0.77 and a 52-week high of $8.65. The company's 50-day moving average price is $1.39 and its two-hundred day moving average price is $1.82. The company has a market cap of $254.65 million, a P/E ratio of -0.36 and a beta of 0.75.
Read Our Latest Research Report on CGC
Aurora Cannabis (ACB)
Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada.
ACB stock traded down $0.11 during mid-day trading on Tuesday, hitting $6.05. The company had a trading volume of 872,930 shares, compared to its average volume of 1,517,719. The company has a market capitalization of $339.81 million, a price-to-earnings ratio of 120.72 and a beta of 1.82. Aurora Cannabis has a 12-month low of $3.42 and a 12-month high of $7.20. The company has a quick ratio of 1.60, a current ratio of 3.30 and a debt-to-equity ratio of 0.07. The company has a 50-day moving average price of $5.01 and a 200 day moving average price of $4.73.
Read Our Latest Research Report on ACB
Incannex Healthcare (IXHL)
Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications.
IXHL stock traded up $0.00 during mid-day trading on Tuesday, hitting $0.21. The company had a trading volume of 22,998,188 shares, compared to its average volume of 30,482,789. The company has a 50-day moving average price of $0.32 and a 200 day moving average price of $1.08. The company has a quick ratio of 1.65, a current ratio of 1.80 and a debt-to-equity ratio of 2.47. The company has a market capitalization of $6.15 million, a price-to-earnings ratio of -0.15 and a beta of 7.63. Incannex Healthcare has a 12-month low of $0.08 and a 12-month high of $3.55.
Read Our Latest Research Report on IXHL
Tilray (TLRY)
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.
Shares of NASDAQ TLRY traded down $0.03 during mid-day trading on Tuesday, hitting $0.40. 11,746,231 shares of the company's stock traded hands, compared to its average volume of 34,174,375. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.54 and a quick ratio of 1.58. Tilray has a 1 year low of $0.37 and a 1 year high of $2.15. The company has a market capitalization of $399.58 million, a P/E ratio of -1.32 and a beta of 1.83. The company's 50-day moving average is $0.45 and its two-hundred day moving average is $0.81.
Read Our Latest Research Report on TLRY
Gibraltar Industries (ROCK)
Gibraltar Industries, Inc. manufactures and provides products and services for the renewable energy, residential, agtech, and infrastructure markets in the United States and internationally. It operates through four segments: Renewables, Residential, Agtech, and Infrastructure. The Renewables segment designs, engineers, manufactures, and installs solar racking and electrical balance of systems for commercial and distributed generation scale solar installations.
Gibraltar Industries stock traded up $0.18 during midday trading on Tuesday, reaching $58.15. The stock had a trading volume of 52,116 shares, compared to its average volume of 228,855. Gibraltar Industries has a 52-week low of $48.96 and a 52-week high of $81.90. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of 13.01 and a beta of 1.34. The company has a fifty day moving average of $57.18 and a 200 day moving average of $60.44.
Read Our Latest Research Report on ROCK
Recommended Stories
Before you consider Quantum Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quantum Biopharma wasn't on the list.
While Quantum Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
